Lista de obras - Fenghuang Zhan - Dominio Público Uruguay

A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma

artículo científico publicado en 1998

ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma

artículo científico publicado en 2013

Adoptive B-cell transfer mouse model of human myeloma

artículo científico publicado en 2015

Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.

artículo científico publicado en 2015

Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.

artículo científico publicado en 2017

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma

artículo científico publicado en 2015

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

artículo científico publicado en 2015

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

artículo científico publicado en 2015

Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.

artículo científico publicado en 2014

Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]

artículo científico publicado en 2018

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

artículo científico publicado en 2001

Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation

artículo científico publicado en 2015

Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.

artículo científico publicado en 2015

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials

artículo científico publicado en 2014

FOXM1 is a therapeutic target for high-risk multiple myeloma

artículo científico publicado en 2015

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

artículo científico publicado en 2005

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

artículo científico publicado en 2008

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

scientific article published on 01 November 2007

Impact of bortezomib on bone health in myeloma: A review of current evidence ⬇️

artículo científico publicado el 9 de enero de 2012

Inhibition of Nek2 by small molecules affects proteasome activity

artículo científico publicado en 2014

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

artículo científico

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens

artículo científico publicado en 2011

Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.

artículo científico publicado en 2012

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells

artículo científico publicado en 2016

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

artículo científico publicado en 2017

Myeloma cell-derived Runx2 promotes myeloma progression in bone.

artículo científico publicado en 2015

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

artículo científico publicado en 2014

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

artículo científico publicado en 2017

Nek2 is a novel regulator of B cell development and immunological response

artículo científico publicado en 2014

Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities

artículo científico publicado en 2014

Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.

artículo científico publicado en 2014

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

artículo científico publicado en 2014

Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations

scientific article published on 11 May 2006

Prognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data

scientific article published on 02 April 2013

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

artículo científico publicado en 2014

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

artículo científico publicado en 2004

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib ⬇️

artículo científico publicado el 14 de mayo de 2013

Role of NEK2A in human cancer and its therapeutic potentials.

artículo científico publicado en 2015

Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma

artículo científico publicado en 2013

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.

artículo científico publicado en 2015

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

artículo científico publicado en 2009

Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling ⬇️

artículo científico publicado el 1 de octubre de 2003

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

artículo científico publicado en 2018

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

artículo científico publicado en 2017

[Myeloma cancer stem cells:the new target for multiple myeloma]

artículo científico publicado en 2014

Lista de obras de Fenghuang Zhan

A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma

ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma

Adoptive B-cell transfer mouse model of human myeloma

Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.

Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.

Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.

Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation

Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials

FOXM1 is a therapeutic target for high-risk multiple myeloma

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

Impact of bortezomib on bone health in myeloma: A review of current evidence ⬇️

Inhibition of Nek2 by small molecules affects proteasome activity

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens

Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

Myeloma cell-derived Runx2 promotes myeloma progression in bone.

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Nek2 is a novel regulator of B cell development and immunological response

Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities

Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations

Prognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib ⬇️

Role of NEK2A in human cancer and its therapeutic potentials.

Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling ⬇️

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

[Myeloma cancer stem cells:the new target for multiple myeloma]